AGI-5198:原理_价格_参数_使用方法-耗材谱::分析测试百科网

溶解性	DMSO 24 mg/mL Water <1 mg/mL Ethanol 14 mg/mL
存贮条件	储存温度-20°C

应用	AGI-5198(IDH C35)是剂量依赖的R132H-IDH1抑制剂
产品介绍	AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
备注	AGI-5198 is the first highly potent and selective inhibitor of IDH1 R132H/R132C mutants with IC50 of 0.07 μM/0.16 μM.
生化机理	Description: IC50 Value: N/A AGI-5198, a novel R132H-IDH1 inhibitor, identified through a high-throughput screen blocked, in a dose-dependent manner, the ability of the mutant enzyme (mIDH1) to produce R-2-hydroxyglutarate (R-2HG). The recent discovery of mutations in metabolic enzymes has rekindled interest in harnessing the altered metabolism of cancer cells for cancer therapy. Isocitrate dehydrogenase 1 (IDH1) is one potential drug target, which is mutated in multiple human cancers [1]. in vitro: N/A in vivo: N/A Clinical trial: N/A
别名	;IDH-C35;AGI5198;AGI 5198;IDH C35;N-Cycohexyl-2-(N-(3-fluorophenyl)-2-(2-methyl-1H-imidazol-1-yl)acetamido)-2-(o-tolyl)acetamide; N-[2-(Cyclohexylamino)-1-(2-methylphenyl)-2-oxoethyl]-N-(3-fluorophenyl)-2-methyl-1H-imidazole-1-acetamide

上海阿拉丁生化科技股份有限公司